Accelerated growth in FY 2026 was led by the Med Tech segment, with strong revenue and margin expansion. FY 2027 guidance anticipates continued double-digit Med Tech growth, stable Med Device sales, and robust cash flow, supported by a strong balance sheet.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.